Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue remains negative

Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 0 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 deferred revenue of $0 is the 4th highest of the 8 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.0% of total assets for PLYX, versus a peer median of 0.0%.
PLYX Competitors Peer median
Deferred Revenue for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FHTXFoghorn Therapeutics Inc.Mar 2026$52.3M +1.2%+9.6%23.5%
CBIOCrescent Biopharma, Inc.Mar 2026$3.12M ——1.6%
PTHSPelthos Therapeutics Inc.Mar 2026$978K ——0.7%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
JBIOJade Biosciences, Inc.Mar 2026$0 ——0.0%
LYELLyell Immunopharma, Inc.Mar 2026$0 ——0.0%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 ——0.0%
KLRSKalaris Therapeutics IncMar 2026$0 ——0.0%
Peer median (excluding PLYX) $0+1.2%+9.6%0.0%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.